Go Pro
→ The $40 billion 'side project' Elon buried inside SpaceX (From The Oxford Club) (Ad)tc pixel Free TBIO Stock Alerts

Telesis Bio (TBIO) Competitors

Telesis Bio logo
$0.0010 0.00 (0.00%)
As of 07/21/2026
Compare

TBIO vs. SPEC, THMO, HTGMQ, PRENW, and SMAPW

Should you buy Telesis Bio stock or one of its competitors? MarketBeat compares Telesis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telesis Bio include Spectaire (SPEC), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), Prenetics Global (PRENW), and SportsMap Tech Acquisition (SMAPW). These companies are all part of the "measuring and control equipment" industry.

How does Telesis Bio compare to Spectaire?

Spectaire (NASDAQ:SPEC) and Telesis Bio (NASDAQ:TBIO) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Spectaire has higher earnings, but lower revenue than Telesis Bio. Spectaire is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectaireN/AN/A$8.95M-$0.30N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

Spectaire has a beta of -6.25, suggesting that its stock price is 725% less volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
SpectaireN/A -81.22% 304.57%
Telesis Bio -336.59%N/A -61.89%

26.5% of Spectaire shares are held by institutional investors. Comparatively, 37.6% of Telesis Bio shares are held by institutional investors. 25.4% of Spectaire shares are held by company insiders. Comparatively, 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
Spectaire Neutral
Telesis Bio Neutral

Summary

Spectaire and Telesis Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Telesis Bio compare to ThermoGenesis?

ThermoGenesis (NASDAQ:THMO) and Telesis Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

5.8% of ThermoGenesis shares are held by institutional investors. Comparatively, 37.6% of Telesis Bio shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by company insiders. Comparatively, 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ThermoGenesis has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Telesis Bio Neutral

ThermoGenesis has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

ThermoGenesis has higher earnings, but lower revenue than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

Summary

ThermoGenesis beats Telesis Bio on 6 of the 9 factors compared between the two stocks.

How does Telesis Bio compare to HTG Molecular Diagnostics?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Telesis Bio (NASDAQ:TBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

HTG Molecular Diagnostics has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

37.6% of Telesis Bio shares are owned by institutional investors. 2.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HTG Molecular Diagnostics has higher earnings, but lower revenue than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

HTG Molecular Diagnostics has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

In the previous week, HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
Telesis Bio Neutral

Summary

HTG Molecular Diagnostics beats Telesis Bio on 5 of the 9 factors compared between the two stocks.

How does Telesis Bio compare to Prenetics Global?

Prenetics Global (NASDAQ:PRENW) and Telesis Bio (NASDAQ:TBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Prenetics Global's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
Prenetics Global Neutral
Telesis Bio Neutral

Prenetics Global has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
Prenetics GlobalN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

Prenetics Global has higher earnings, but lower revenue than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prenetics Global$120.07MN/AN/AN/AN/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

37.6% of Telesis Bio shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Telesis Bio beats Prenetics Global on 3 of the 5 factors compared between the two stocks.

How does Telesis Bio compare to SportsMap Tech Acquisition?

SportsMap Tech Acquisition (NASDAQ:SMAPW) and Telesis Bio (NASDAQ:TBIO) are both measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, SportsMap Tech Acquisition's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
SportsMap Tech Acquisition Neutral
Telesis Bio Neutral

SportsMap Tech Acquisition has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
SportsMap Tech AcquisitionN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

37.6% of Telesis Bio shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SportsMap Tech Acquisition has higher earnings, but lower revenue than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SportsMap Tech AcquisitionN/AN/AN/AN/AN/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

Summary

Telesis Bio beats SportsMap Tech Acquisition on 3 of the 5 factors compared between the two stocks.

Get Telesis Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TBIO vs. The Competition

Export
MetricTelesis BioAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$2K$2K$7.01B$12.68B
Dividend YieldN/AN/A2.67%9.42%
P/E Ratio0.00N/A26.8823.95
Price / Sales0.000.00518.3693.75
Price / CashN/AN/A50.6060.45
Price / Book0.010.0110.566.16
Net Income-$47.72M-$47.72M$3.60B$331.73M
7 Day PerformanceN/AN/A-2.15%-1.96%
1 Month PerformanceN/AN/A0.10%-2.49%
1 Year PerformanceN/AN/A22.55%17.21%

Telesis Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBIO
Telesis Bio
N/A$0.00
flat		N/A-95.9%$2K$225.09MN/A200
SPEC
Spectaire
N/A$0.00
flat		N/AN/A$9KN/AN/A8
THMO
ThermoGenesis
N/AN/AN/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
PRENW
Prenetics Global
N/A$0.02
+2.3%		N/A-77.1%$0.00$120.07MN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TBIO) was last updated on 7/22/2026 by MarketBeat.com Staff.
From Our Partners
America’s answer to universal basic income
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
TSM just handed Trump's secretive AI project $100 billion
Taiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...
InvestorPlace | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon is about to dominate the biggest arms race in tech history
Microsoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...
The Oxford Club | Sponsoredtc pixel
Wall Street legend put 60% in one stock — here’s the ticker
One of America's most famous investors put 60% of his fund into a single stock - and Whitney Tilson of Stansbe...
Stansberry Research | Sponsoredtc pixel
It all happens tonight.
Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...
Trade Thirsty | Sponsoredtc pixel